Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Results symbols : Chrs save search
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Published: 2024-03-06 (Crawled : 21:00) - prnewswire.com
INO 3 d | $10.22 -7.68% -8.32% 400K
|
Health Technology
|
| O: -2.23%
H: 0.62%
C: -6.42%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.45%
H: 1.13%
C: -0.45%
year financial results
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 2.29%
H: 4.04%
C: -0.9%
report year financial results
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Published: 2023-11-28 (Crawled : 16:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -1.55%
H: 12.83%
C: 10.47%
piter-02 association positive publication treatment medical trial results
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
VCNX | $4.71 -2.69% -2.76% 11K
|
Health Technology
|
| O: 2.76%
H: 1.08%
C: -3.23%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.63%
H: 8.12%
C: 7.5%
update financial results
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -22.6%
H: 3.28%
C: -9.85%
business financial results
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
Published: 2023-10-30 (Crawled : 22:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -5.32%
H: 19.65%
C: 17.54%
report financial results
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-08-14 (Crawled : 12:00) - ir.vaccinex.com
VCNX | $4.71 -2.69% -2.76% 11K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: -8.08%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -1.99%
H: 0.21%
C: -3.0%
update financial results
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
Published: 2023-08-02 (Crawled : 20:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.06%
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 3.49%
H: 14.13%
C: 10.87%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 9.45%
H: 10.53%
C: 7.58%
business financial results
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
Published: 2023-07-26 (Crawled : 20:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.55%
H: 2.83%
C: 0.0%
report financial results
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Published: 2023-06-05 (Crawled : 22:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.45%
H: 0.05%
C: -1.48%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.4%
H: 9.6%
C: 5.4%
piter-02 positive trial results
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
Published: 2023-05-08 (Crawled : 20:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.03%
H: 0.71%
C: -0.39%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -20.64%
H: 0.93%
C: -8.51%
business financial results
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
Published: 2023-05-01 (Crawled : 20:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -0.65%
H: 0.79%
C: -5.91%
report financial results
Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates
Published: 2023-03-31 (Crawled : 09:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.24%
H: 5.38%
C: 5.07%
year financial results
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
Published: 2023-03-06 (Crawled : 21:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -3.55%
H: 12.33%
C: 11.79%
year results
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -1.0%
H: 1.45%
C: -2.17%
report year financial results
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.61%
H: 1.13%
C: -0.9%
report financial results
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab
Published: 2022-10-12 (Crawled : 12:00) - biospace.com/
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -1.15%
H: 1.63%
C: -0.93%
hoice-01 trial positive results publication
Junshi Biosciences Announces 2022 Interim Financial Results and Provides Corporate Updates
Published: 2022-08-31 (Crawled : 06:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.93%
H: 0.95%
C: -3.87%
results
Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022
Published: 2022-04-29 (Crawled : 13:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 3.09%
H: 0.0%
C: 0.0%
report results
Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
Published: 2022-04-09 (Crawled : 04:20) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
| Email alert
Add to watchlist
treatment results phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.